Eszopiclone

Drug Profile

Eszopiclone

Alternative Names: Esopiclone; Estorra; Lunesta; Lunivia; S-Zopiclone; SEP-0227018; SEP-190; SEP-225441; Zopiclone - Sunovion

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Eisai Co Ltd; Sepracor; Sunovion Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Esters; Hypnosedatives; Piperazines; Pyrazines; Pyridines; Pyrroles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia
  • No development reported Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 01 Oct 2016 Eisai initiates enrolment in a clinical trial for Insomnia in Japan (UMIN000024462)
  • 29 Apr 2016 Biomarkers information updated
  • 15 Apr 2014 Generic equivalent available in USA for Insomnia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top